-
1دورية أكاديمية
المؤلفون: Reschke, F, Lanzinger, S, Herczeg, V, Prahalad, P, Schiaffini, R, Mul, D, Clapin, H, Zabeen, B, Pelicand, J, Phillip, M, Limbert, C, Danne, T, Alonso, GT, Rhodes, ET, Davis, E, Veeze, HJ, Maahs, D, Cardona-Hernandez, R, Sumnik, Z, Corathers, S, Bratina, N, Gevers, E, Imane, Z, Piccini, B, Forsander, G, Pacaud, D, Maffeis, C, Campbell, F, Bonfanti, R, de Sanctis, L, Krone, RE, Toth-Heyn, P, Witsch, M, Arsanoglu, I, Jefferies, C, Landry, A, Beltrand, J, Amed, S, Rami-Merhar, B, Barat, P, Szypowska, A, Casteels, K, Savova, R, Cherubini, V, de Bock, M, Todorovic, S, Moravej, H, Pozgaj Sepac, M, Mazur, A, Gerasimidou-Vazeou, A, Iotova, V, O’Riordan, S, Chobot, A, Herbst, A, Ngwu, U, Cody, D, Birkebæk, NH, Hanas, R, Goksen, D, Sarda, A, Chobot, J, Mirante, A, Richmond Padilla, E, Tsiroukidou, K, Saboo, B, Kanaka-Gantenbein, C, Foskett, D, Jali, S, Verkauskiene, R, Castro-Correia, C, Kumar Guness, P, Cotterill, A, Kumari Mohan, M, Spehar Uroic, A, Goss, P, Svensson, J, Ramchandani, GD, Coutant, R, Mantilla, L, Sima, A, Hyun Kim, J, Galli-Tsinopoulou, A, Ribeiro, R, O’Gorman, C, Fonna, H, Bratke, H, El Habashy, S, Gokalani, R, Scharf Pinto, M, Chavda, V
مصطلحات موضوعية: Adolescent, COVID-19, Child, Communicable Disease Control, Pandemics, Diabetes Mellitus, Type 1* / epidemiology, Glycated Hemoglobin, Registries, HDE END PED
الوصف: Objective: To analyze whether the coronavirus disease 2019 (COVID-19) pandemic increased the number of cases or impacted seasonality of new-onset type 1 diabetes (T1D) in large pediatric diabetes centers globally. Research design and methods: We analyzed data on 17,280 cases of T1D diagnosed during 2018-2021 from 92 worldwide centers participating in the SWEET registry using hierarchic linear regression models. Results: The average number of new-onset T1D cases per center adjusted for the total number of patients treated at the center per year and stratified by age-groups increased from 11.2 (95% CI 10.1-12.2) in 2018 to 21.7 (20.6-22.8) in 2021 for the youngest age-group, <6 years; from 13.1 (12.2-14.0) in 2018 to 26.7 (25.7-27.7) in 2021 for children ages 6 to <12 years; and from 12.2 (11.5-12.9) to 24.7 (24.0-25.5) for adolescents ages 12-18 years (all P < 0.001). These increases remained within the expected increase with the 95% CI of the regression line. However, in Europe and North America following the lockdown early in 2020, the typical seasonality of more cases during winter season was delayed, with a peak during the summer and autumn months. While the seasonal pattern in Europe returned to prepandemic times in 2021, this was not the case in North America. Compared with 2018-2019 (HbA1c 7.7%), higher average HbA1c levels (2020, 8.1%; 2021, 8.6%; P < 0.001) were present within the first year of T1D during the pandemic. Conclusions: The slope of the rise in pediatric new-onset T1D in SWEET centers remained unchanged during the COVID-19 pandemic, but a change in the seasonality at onset became apparent. ; info:eu-repo/semantics/publishedVersion
العلاقة: Diabetes Care . 2022 Nov 1;45(11):2594-2601; http://hdl.handle.net/10400.17/4770Test
-
2
المؤلفون: Lanzinger, S., Zimmermann, A., Ranjan, A. G., Gani, O., Perez, S. P., Akesson, K., Majidi, S., Witsch, M., Hofer, S., Johnson, S., Pilgaard, K. A., Kummernes, S. J., Robinson, H., Eeg-Olofsson, Katarina, 1968, Ebekozien, O., Holl, R. W., Svensson, J., Skrivarhaug, T., Warner, J., Craig, M. E., Maahs, D.
المصدر: Pediatric Diabetes. 23(6):627-640
مصطلحات موضوعية: Pediatrics, Pediatrik, Endocrinology and Diabetes, Endokrinologi och diabetes, benchmarking, diabetes mellitus, network, quality improvement, registry, hba(1c) levels, children, adolescents, childhood, care, Endocrinology & Metabolism
الوصف: Background An estimated 1.1 million children and adolescents aged under 20 years have type 1 diabetes worldwide. Principal investigators from seven well-established longitudinal pediatric diabetes registries and the SWEET initiative have come together to provide an international collaborative perspective and comparison of the registries. Work Flow Information and data including registry characteristics, pediatric participant clinical characteristics, data availability and data completeness from the Australasian Diabetes Data Network (ADDN), Danish Registry of Childhood and Adolescent Diabetes (DanDiabKids), Diabetes prospective follow-up registry (DPV), Norwegian Childhood Diabetes Registry (NCDR), National Paediatric Diabetes Audit (NPDA), Swedish Childhood Diabetes Registry (Swediabkids), T1D Exchange Quality Improvement Collaborative (T1DX-QI), and the SWEET initiative was extracted up until 31 December 2020. Registry Objectives and Outcomes The seven diabetes registries and the SWEET initiative collectively show data of more than 900 centers and around 100,000 pediatric patients, the majority with type 1 diabetes. All share the common objectives of monitoring treatment and longitudinal outcomes, promoting quality improvement and equality in diabetes care and enabling clinical research. All generate regular benchmark reports. Main differences were observed in the definition of the pediatric population, the inclusion of adults, documentation of CGM metrics and collection of raw data files as well as linkage to other data sources. The open benchmarking and access to regularly updated data may prove to be the most important contribution from registries. This study describes aspects of the registries to enable future collaborations and to encourage the development of new registries where they do not exist.
الوصول الحر: https://gup.ub.gu.se/publication/317058Test
-
3
المؤلفون: Sumnik, Z., Szypowska, A., Iotova, V., Bratina, N., Cherubini, V., Forsander, Gun, 1951, Jali, S., Raposo, J. F., Stipančic, G., Vazeou, A., Veeze, H., Lange, K., Papo, N., Kownatka, D., Lion, S., Gerhardsson, P., Kalina, T., Rami-Merhar, B., Svensson, J., Hanas, R., Knip, M., Witsch, M., Verkauskiene, R., Todorovic, S., Toth-Heyn, P., Ng, M., Pelicand, J., Podolakova, K., Timar, B., Casteels, K., Cordona Hernandez, R., Hoey, H.
المصدر: Pediatric Diabetes. 20(4):434-443
مصطلحات موضوعية: Pediatrics, Pediatrik, Endocrinology and Diabetes, Endokrinologi och diabetes, children, diabetes technology, reimbursement, type 1 diabetes
الوصف: Background: Frequent use of modern diabetes technologies increases the chance for optimal type 1 diabetes (T1D) control. Limited reimbursement influences the access of patients with T1D to these modalities and could worsen their prognosis. We aimed to describe the situation of reimbursement for insulins, glucometers, insulin pumps (CSII) and continuous glucose monitoring (CGM) for children with T1D in European countries participating in the SWEET Project and to compare data from EU countries with data from our previous study in 2009. Methods: The study was conducted between March 2017 and August 2017. First, we approached diabetes technology companies with a survey to map the reimbursement of insulins and diabetic devices. The data collected from these companies were then validated by members of the SWEET consortium. Results: We collected data from 29 European countries, whereas all types of insulins are mostly fully covered, heterogeneity was observed regarding the reimbursement of strips for glucometers (from 90 strips/month to no limit). CSII is readily available in 20 of 29 countries. Seven countries reported significant quota issues or obstacles for CSII prescription, and two countries had no CSII reimbursement. CGM is at least partially reimbursed in 17 of 29 countries. The comparison with the 2009 study showed an increasing availability of CSII and CGM across the EU. Conclusions: Although innovative diabetes technology is available, a large proportion of children with T1D still do not benefit from it due to its limited reimbursement. © 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
الوصول الحر: https://gup.ub.gu.se/publication/281602Test
-
4مؤتمر
المؤلفون: Hermann, J, Hrabe de Angelis, M, Pieber, T, Boettcher, C, Witsch, M, Pavel, M, Holl, RW
المصدر: Diabetes – Nicht nur eine Typ-Frage – www.diabeteskongress.de ; Diabetologie und Stoffwechsel ; ISSN 1861-9010
-
5
المؤلفون: Gerhardsson, P., Schwandt, A., Witsch, M., Kordonouri, O., Svensson, J., Forsander, Gun, 1951, Battelino, T., Veeze, H., Danne, T., Sweet Study Grp, Sweet Study Grp
المصدر: Diabetes Technology & Therapeutics. 23(7)
مصطلحات موضوعية: Endocrinology and Diabetes, Endokrinologi och diabetes, Type-1 diabetes, Hemoglobin A1c, Benchmarking, Insulin pumps, Continuous, glucose monitoring, Hypoglycemia, Diabetic ketoacidosis, the SWEET, project, Diabetes registry, Glycemic control, Endocrinology & Metabolism
الوصف: Objective: The international SWEET registry (NCT04427189) was initiated in 2008 to improve outcomes in pediatric diabetes. A 10-year follow-up allowed studying time trends of key quality indicators in 22 centers from Europe, Australia, Canada, and India in youth with type 1 diabetes (T1D). Methods: Aggregated data per person with T1D <25 years of age were compared between 2008-2010 and 2016-2018. Hierarchic linear and logistic regression models were applied. Models were adjusted for gender, age-, and diabetes duration groups. Results: The first and second time periods included 4930 versus 13,654 persons, 51% versus 52% male, median age 11.3 [Q1; Q3: 7.9; 14.5] versus 13.3 [9.7; 16.4] years, and T1D duration 2.9 [0.8; 6.4] versus 4.2 [1.4; 7.7] years. The adjusted hemoglobin A1C (HbA1c) improved from 68 (95% confidence interval [CI]: 66-70) to 63 (60; 65) mmol/mol (P<0.0001) or 8.4 (95% CI: 8.2-8.6) to 7.9 (7.6; 8.1) % (P<0.0001). Across all age groups, HbA1c was significantly lower in pump and sensor users. Severe hypoglycemia declined from 3.8% (2.9; 5.0) to 2.4% (1.9; 3.1) (P<0.0001), whereas diabetic ketoacidosis events increased significantly with injection therapy only. Body mass index-standard deviation score also showed significant improvements 0.55 (0.46; 0.64) versus 0.42 (0.33; 0.51) (P<0.0001). Over time, the increase in pump use from 34% to 44% preceded the increase in HbA1c target achievement (<53mmol/mol) from 21% to 34%. Conclusions: Twice yearly benchmarking within the SWEET registry was associated with significantly improved HbA1c on a background of increasing pump and sensor use for 10 years in young persons with T1D.
الوصول الحر: https://gup.ub.gu.se/publication/306118Test
-
6دورية أكاديمية
المؤلفون: Schwandt, A., Kuss, O., Dpv Initiative, Dunstheimer, D. P., Karges, Beate Maria, Kapellen, T. M., Meissner, T., Witsch, M., Flury, M., Straubinger, S., Holl, R. W.
المصدر: Diabetes : a journal of the American Diabetes Association 68(Supplement 1), 1362-P (2019). doi:10.2337/db19-1362-P special issue: "Poster Presentations: Clinical Diabetes/Therapeutics"
جغرافية الموضوع: DE
العلاقة: info:eu-repo/semantics/altIdentifier/issn/0012-1797; info:eu-repo/semantics/altIdentifier/issn/1939-327X; info:eu-repo/semantics/altIdentifier/wos/WOS:000501366903246; https://publications.rwth-aachen.de/record/785931Test; https://publications.rwth-aachen.de/search?p=id:%22RWTH-CONV-241238%22Test
-
7دورية أكاديمية
المؤلفون: Pacaud, D., Hermann, J. M., Raile, K., Witsch, M., Holl, R. W., DPV Initiative, Karges, Beate Maria, Rosenbauer, J., Danne, T., Dürr, R., Herbst, A., Lindauer, S., Müther, S., Pötzsch, S.
المصدر: Pediatric diabetes 19(3), 493-500 (2018). doi:10.1111/pedi.12610
جغرافية الموضوع: DE
العلاقة: info:eu-repo/semantics/altIdentifier/issn/1399-5448; info:eu-repo/semantics/altIdentifier/issn/1399-543X; info:eu-repo/semantics/altIdentifier/pmid/pmid:29218766; info:eu-repo/semantics/altIdentifier/wos/WOS:000430921600023; https://publications.rwth-aachen.de/record/757339Test; https://publications.rwth-aachen.de/search?p=id:%22RWTH-CONV-237400%22Test
-
8دورية أكاديمية
المؤلفون: Gerasimidi Vazeou, A, Kordonouri, O, Witsch, M, Hermann, J M, Forsander, G, de Beaufort, C, Veeze, H J, Maffeis, C, Cherubini, V, Cinek, O, Piccini, B, Holl, R W, Danne, T
المساهمون: Gerasimidi Vazeou, A, Kordonouri, O, Witsch, M, Hermann, J M, Forsander, G, de Beaufort, C, Veeze, H J, Maffeis, C, Cherubini, V, Cinek, O, Piccini, B, Holl, R W, Danne, T
مصطلحات موضوعية: SWEET centre, SWEET database, seasonality, type 1 diabete, type 1 diabetes etiopathogenesi, Adolescent, Child, Preschool, Cohort Studie, Diabetes Mellitus, Type 1, Europe, Female, Human, Infant, Male, Young Adult, Seasons
الوصف: Background: Seasonality at the clinical onset of type 1 diabetes (T1D) has been suggested by different studies, however, the results are conflicting. This study aimed to evaluate the presence of seasonality at clinical onset of T1D based on the SWEET database comprising data from 32 different countries. Methods: The study cohort included 23 603 patients (52% males) recorded in the international multicenter SWEET database (48 centers), with T1D onset ≤20 years, year of onset between 1980 and 2015, gender, year and month of birth and T1D-diagnosis documented. Data were stratified according to four age groups (<5, 5-<10, 10-<15, 15-20 years) at T1D onset, the latitude of European center (Northern ≥50°N and Southern Europe <50°N) and the year of onset ≤ or >2009. Results: Analysis by month revealed significant seasonality with January being the month with the highest and June with the lowest percentage of incident cases (P <.001). Winter, early spring and late autumn months had higher percentage of incident cases compared with late spring and summer months. Stratification by age showed similar seasonality patterns in all four age groups (P ≤.003 each), but not in children <24 months of age. There was no gender or latitude effect on seasonality pattern, however, the pattern differed by the year of onset (P <.001). Seasonality of diagnosis conformed to a sinusoidal model for all cases, females and males, age groups, northern and southern European countries. Conclusions: Seasonality at T1D clinical onset is documented by the large SWEET database with no gender or latitude (Europe only) effect except from the year of manifestation.
وصف الملف: STAMPA
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/28334496; info:eu-repo/semantics/altIdentifier/wos/WOS:000389153800005; volume:17; issue:S23; firstpage:32; lastpage:37; numberofpages:6; journal:PEDIATRIC DIABETES; http://hdl.handle.net/11562/972876Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84992371576
-
9
المؤلفون: M. Dahlheim, Witsch M, Süha Demirakca, Lorenz C, Thomas Schaible
المصدر: Klinische Pädiatrie. 215:213-222
مصطلحات موضوعية: medicine.medical_specialty, business.industry, Birth weight, medicine.medical_treatment, Respiratory disease, High-frequency ventilation, Congenital diaphragmatic hernia, medicine.disease, Surgery, Diaphragm (structural system), surgical procedures, operative, Pediatrics, Perinatology and Child Health, medicine, Breathing, Hernia, business, Survival rate
الوصف: Background: In recent years increasing survival rates of neonates with congenital diaphragmatic hernia were reported. We present the results of our collective with regard to outcome and predictors of prognosis (need for ECMO, survival). Patients and methods: The neonates with congenital diaphragmatic hernia treated between December 1997 and June 2001 in the university children's hospital Mannheim were included. All patients with congenital diaphragmatic hernia were treated by a defined algorithm including prenatal pulmonary maturation, surfactant immediately after birth, gentle ventilation, inhaled NO, high frequency ventilation and, if necessary, ECMO. We looked at early predictors of the clinical course, e.g. need for ECMO and survival: Birth weight, oxygenation index, ventilation index, the highest and the lowest arterial oxygen and the lowest carbon dioxide partial pressures during the first 24 hours in the ECMO-centre. Results: Between December 1997 and June 2001 50 neonates with congenital diaphragmatic hernia were treated (24 inborn, all of them diagnosed prenatally, 26 transfered after birth). Mean OI was 45,5 cmH 2 O/mmHg (no ECMO: 16,4 cmH 2 O/ mmHg; ECMO: 62,1 cmH2O/mmHg) mean VI was 133,8 cmH 2 O x mmHg (no ECMO: 83,9 cmH 2 O x mmHg; ECMO: 156,2 cmH 2 O x mmHg).The survival rate was 84%. According to our algorithm 50% of the patients were treated with ECMO, 78% of the patients treated with ECMO survived. 3 Patients were excluded by the therapy option ECMO, because of contraindications. If the patients need to be treated with ECMO, the predictors of prognosis do not allow to draw conclusions on the clinical course regarding the survival of the patients. Conclusion: Our algorithm allows a good survival rate in patients with congenital diaphragmatic hernia. CDH patients seem to have a benefit from transfer into an ECMO centre as early as possible or prenatally. There is no basis according our experiences to exclude patients with congenital diaphragmatic hernia from ECMO. To evaluate the predictors of prognosis regarding the question, which patients do not require ECMO, which patients have a benefit of ecmo, and which patients will die despite ecmo a nationwide cdh-register could be helpfull.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::d0c0a82671b989fedc0a41a9ad9aeb3dTest
https://doi.org/10.1055/s-2003-41400Test -
10
المؤلفون: von Witsch M, Markus Braun, František Baluška, D Menzel
المصدر: Planta. 209:435-443
مصطلحات موضوعية: biology, Actin remodeling, macromolecular substances, Plant Science, Root hair, Microfilament, Actin remodeling of neurons, Profilin, Biochemistry, Genetics, biology.protein, Biophysics, MDia1, Tip growth, Cytoskeleton
الوصف: The continuously changing polar cytoplasmic organization during initiation and tip growth of root hairs is reflected by a dynamic redistribution of cytoskeletal elements. The small G-actin binding protein, profilin, which is known to be a widely expressed, potent regulator of actin dynamics, was specifically localized at the tip of root hairs and co-distributed with a diffusely fluorescing apical cap of actin, but not with subapical actin microfilament (MF) bundles. Profilin and actin caps were present exclusively in the bulge of outgrowing root hairs and at the apex of elongating root hairs; both disappeared when tip growth terminated, indicating a tip-growth mechanism that involves profilin-actin interactions for the delivery and localized exocytosis of secretory vesicles. Phosphatidylinositol-4,5-bisphosphate (PIP(2)), a ligand of profilin, was localized almost exclusively in the bulge and, subsequently, formed a weak tip-to-base gradient in the elongating root hairs. When tip growth was eliminated by the MF-disrupting inhibitor cytochalasin D, the apical profilin and the actin fluorescence were lost. Mastoparan, which is known to affect the PIP(2) cycle, probably by stimulating phospholipases, caused the formation of a meshwork of distinct actin MFs replacing the diffuse apical actin cap and, concomittantly, tip growth stopped. This suggests that mastoparan interferes with the PIP(2)-regulated profilin-actin interactions and hence disturbs conditions indispensable for the maintenance of tip growth in root hairs.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c90b69dcbaef2efd793a8f4d37813d97Test
https://doi.org/10.1007/s004250050746Test
